Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03989037
Recruitment Status : Recruiting
First Posted : June 18, 2019
Last Update Posted : June 18, 2019
Sponsor:
Collaborator:
Fudan University
Information provided by (Responsible Party):
Shanghai Institute Of Biological Products

Brief Summary:
The study will compare PK, efficacy, safety, and immunogenicity of SIBP-01 (Trastuzumab Biosimilar) in combination with Docetaxel and Carboplatin versus Herceptin® (CN-Trastuzumab) approved in the CN in combination with Docetaxel and Carboplatin in patients with operable HER2 positive, with early or locally advanced HER2-positive breast cancer. The hypothesis to be tested in this study is the tpCR of patients with Cycle 6 of SIBP-01 is similar to CN-approved trastuzumab, using a 90% bilateral confidence interval between 0.74 and 1.5.

Condition or disease Intervention/treatment Phase
HER2-positive Early Breast Cancer Drug: SIBP-01 Drug: Herceptin Drug: Docetaxel Drug: Carboplatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 580 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center, randomized, single-blind, positive drug parallel controlled equivalence clinical trial.
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Single-blind Study Comparing the Efficacy, Safety, and Immunogenicity of SIBP-01 and CN-Trastuzumab Combination With Docetaxel and Carboplatin in Patients With Early or Locally Advanced Her2 Positive Breast Cancer
Estimated Study Start Date : June 30, 2019
Estimated Primary Completion Date : May 28, 2021
Estimated Study Completion Date : July 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: SIBP-01 & Docetaxel & Carboplatin
SIBP-01→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; SIBP-01: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
Drug: SIBP-01
IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Other Name: Herceptin Biosimilar

Drug: Docetaxel
Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
Other Name: Docetaxel Injection

Drug: Carboplatin
Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Other Name: PARAPLATIN®,Carboplatin Injection

Active Comparator: Herceptin & Docetaxel & Carboplatin
Herceptin→ Docetaxel→ Carboplatin: injection, every 3 weeks for 18 weeks; Herceptin: first dose 8mg/kg, then 6mg/kg; Docetaxel: dose 75mg/m2; Carboplatin: dose AUC6
Drug: Herceptin
Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Other Name: Trastuzumab

Drug: Docetaxel
Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
Other Name: Docetaxel Injection

Drug: Carboplatin
Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Other Name: PARAPLATIN®,Carboplatin Injection




Primary Outcome Measures :
  1. Total pathologic complete response (tpCR) [ Time Frame: at the end of Cycle 6(each cycle is 3 weeks) ]
    Total Pathologic Complete Response (tpCR) Defined as the Absence of Invasive Neoplastic Cells in the Breast and Lymph Nodes(ypT0/is, ypN0). Following surgery after treatment completion, tumors were assessed as Complete Pathological Response, Partial Pathological Response, or No Pathological Response..The tpCR was assessed by the Independent Response Evaluation Committee (IREC)


Secondary Outcome Measures :
  1. Breast pathologic complete response (bpCR) [ Time Frame: at the end of Cycle 6(each cycle is 3 weeks) ]
    Pathologic Complete Response (pCR) Defined as the Absence of Invasive Neoplastic Cells in the Breast and Lymph Nodes(ypT0/is). Following surgery after treatment completion, tumors were assessed as Complete Pathological Response, Partial Pathological Response, or No Pathological Response.

  2. Proportion of patients with steady-state trough concentration (Ctrough, ss) > 20 μg/mL [ Time Frame: after 5 cycles of treatment ( before cycle 6, each cycle is 3 weeks) ]
    proportion of patients with Ctrough, ss> 20 μg/mL after 5 cycles of administration (before cycle 6) accounting for all subjects with PK blood samples collected in each treatment group

  3. PK Evaluation After Multi-Dose Administration [ Time Frame: Cycles 1 through 6 ( each cycle is 3 weeks ) ]
    Samples of blood were taken pre-dose on Cycles 1, 2, 3, 4, 5, and 6, and at 0, 2, 4, 8, 72, 168, 336 hour post dose on Cycles 5 and 21 days post dose on cycle 6 for pharmacokinetic evaluation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female patients with HER2-positive breast cancer
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Those voluntarily signing the informed consent form, understanding the study and willing to follow all testing procedures;
  • Females aged ≥ 18 years and ≤ 75 years (at the date of signing the informed consent form);
  • Patients diagnosed with early (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0) invasive breast cancer histologically;
  • Patients with HER2-positive breast cancer: HER2 detection is based on the Chinese Breast Cancer HER2 Detection Guidelines (2019 Edition), the immunohistochemistry (IHC) method is used to detect the expression level of HER2 protein, and the in situ hybridization (ISH) method is used to detect the HER2 gene amplification level. ISH includes fluorescence in situ hybridization (FISH) and bright-field in situ hybridization. The common bright-field in situ hybridization method includes chromogenic in situ hybridization (CISH) and silver-enhanced in situ hybridization (SISH);The HER2-positive criterion is: IHC detection +++, or IHC++, and further in situ hybridization confirms that HER2 gene amplification is positive;
  • Those planning to receive final surgical resection of breast cancer, i.e. breast-conserving surgery or total mastectomy, sentinel node (SN) biopsy or axillary lymph node dissection (ALND);
  • Those planning to receive neoadjuvant chemotherapy;
  • Those with the maximum primary tumor diameter of > 2cm determined by the standard evaluation method of study center (MRI);
  • Patients with performance status score of 0 or 1 by the US Eastern Cooperative Oncology Group (ECOG);
  • Those with left ventricular ejection fraction (LVEF) of ≥ 55% within 4 weeks prior to randomized enrollment; 10) Those with suitable organs and hematopoietic functions, without significant abnormality in the following laboratory examinations:

    • Absolute neutrophil count (NEUT#) ≥1.5×109/L;
    • Absolute white blood cell count (WBC) ≥ 3.0 × 109/L;
    • Platelet ≥90×109/L;
    • Hemoglobin ≥90g/L;
    • Serum creatinine ≤1.5 x upper limit of normal (ULN);
    • AST and ALT values ≤ 1.5 x ULN;
    • Serum total bilirubin (TBIL) ≤ 1.5 x ULN;
    • International normalized ratio (INR) ≤ 1.5 x ULN, or activated partial thromboplastin time (APTT) ≤ 1.5 x ULN (except for subjects undergoing anticoagulation therapy).

(The above laboratory examinations are subject to the normal values of each clinical research center)

  • Female patients without menopause or surgical sterilization: they agree to practice abstinence or effective contraception during treatment and at least 7 months after the last administration in the study treatment.

Women at childbearing age who have undergone surgical sterilization (including hysterectomy, bilateral oophorectomy or total hysterectomy) or have been menopausal (defined as having no menstruation for more than 12 months without medical reason) are considered as having no possibility of pregnancy.

Throughout the clinical trial, women with the possibility of pregnancy are willing to practice medically accepted, effective contraception, including intrauterine contraceptive device.

Exclusion Criteria:

  • Pregnant or lactating women, and patients with positive baseline pregnancy test; women of childbearing age who do not agree to practice abstinence or effective contraception during the study period and within 7 months after the last administration;
  • Those with a clear history of drug allergy, especially those with prior severe allergic reaction to macromolecular protein preparation/monoclonal antibody, or to any of the test drug components (NCI-CTCAE 5.0 greater than grade 3);
  • Patients with bilateral breast cancer or inflammatory breast cancer;
  • Patients with (metastatic) breast cancer Stage IV;
  • Those with a history of congestive heart failure, unstable angina, arrhythmia or myocardial infarction;
  • Those with other invasive tumors (including second primary breast cancer) that might affect the result evaluation and protocol compliance; however, subjects who are cured with a disease-free survival of at least 5 years may be enrolled;
  • Patients with breast cancer who have previously received chemotherapy, endocrine therapy, or anti-HER2 biotherapy, or have received breast surgery (except for diagnostic biopsy of primary breast cancer);
  • Those with known, uncontrolled, active bacterial, viral, fungal, mycobacterial, parasitic or other infections (excluding nail bed fungal infection) or with any significant systemic infection event that required intravenous antibiotic treatment or hospitalization (except for neoplastic fever) within 4 weeks prior to enrollment);
  • Those with any positive HIV antibody or treponema pallidum antibody;
  • Those with active hepatitis B (hepatitis B virus DNA titer is above the lower limit of normal);
  • Those with existing, sudden lung disease, interstitial lung disease, pneumonia or pulmonary fibrosis, except for local interstitial pneumonia induced by radiotherapy;
  • Those with a prior history of drug abuse, alcohol abuse or drug addiction;
  • Those with a clear history of neurological or mental disease and with poor compliance, such as epilepsy and dementia;
  • Those with a major surgical operation or infusion of blood or blood components 4 weeks prior to the clinical trial;
  • Those with blood loss or donation of more than 400 ml within the 2 months prior to the clinical trial;
  • Those who have participated in other clinical trials 3 months prior to this clinical trial;
  • Those with reduced possibility of enrollment (e.g. weakness) or non-compliance tendency during the study period, or with other diseases that might complicate enrollment as judged by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03989037


Contacts
Layout table for location contacts
Contact: Aidong QU, phD +86-021-62800991 quaidong1@sinopharm.com
Contact: Dandan Chen, Master +86-021-62800991 ddchen.sh@sinopharm.com

Locations
Layout table for location information
China, Shanghai
Fudan University Shanghai Cancer Center Recruiting
Shanghai, Shanghai, China, 200032
Contact: Jiong Wu, PhD    +86-021-64175590-88607    wujiong1122@vip.sina.com   
Sponsors and Collaborators
Shanghai Institute Of Biological Products
Fudan University
Investigators
Layout table for investigator information
Study Director: Shanghai Institute Of Biological Products Co., Ltd SINOPHARM
Principal Investigator: Fudan University Shanghai Cancer Center Fudan University

Publications of Results:
Layout table for additonal information
Responsible Party: Shanghai Institute Of Biological Products
ClinicalTrials.gov Identifier: NCT03989037     History of Changes
Other Study ID Numbers: SIBP-01-3
First Posted: June 18, 2019    Key Record Dates
Last Update Posted: June 18, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Carboplatin
Docetaxel
Trastuzumab
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological